The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model

Slični predmeti

• Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies
  od: Krendyukov A, i dr.
  Izdano: (2019-09-01)
• CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence
  od: Richards DM, i dr.
  Izdano: (2021-03-01)
• Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
  od: Nina Hanke, i dr.
  Izdano: (2019-04-01)
• Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trialResearch in context
  od: Maria Pilar Ruiz Seco, i dr.
  Izdano: (2024-11-01)
• The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence
  od: Charlotte Lemech, i dr.
  Izdano: (2012-03-01)